No. Three residues have two peptide bonds and no capacity for secondary structure. Any activity comes from side-chain chemistry and proline's local geometry.

Can it be quantified at 280 nm?

No. There is no aromatic residue, so there is no usable absorbance there.

Why does one proline matter so much?

In a tripeptide it is a third of the molecule. It locks local geometry and makes adjacent bonds poor protease substrates.

KPV

KPV Structure and Physical Properties

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

KPV is Lys-Pro-Val: three residues, 342.43 Da, formula C16H30N4O4. Lysine gives it positive charge, proline provides the only conformational constraint, and valine's branched side chain terminates it. No cysteine, no methionine, no aromatic residue.

Key facts

Sequence: Lys-Pro-Val
Molecular weight: 342.43 Da
Formula: C16H30N4O4
PubChem CID: 125672
Charge: Positive — one lysine
Constraint: One proline
Aromatic residues: None

What three residues can do

Very little structurally. A tripeptide has two peptide bonds and essentially no capacity for secondary structure — no helix, no sheet, no folded core. Whatever activity it has must come from the chemistry of its side chains and the local geometry proline imposes, not from any three-dimensional arrangement.

Each residue's contribution

Lysine's side chain amine is positively charged at physiological pH, which drives water solubility and interaction with negatively charged surfaces. Proline is the only conformational constraint present — its ring locks local backbone geometry and makes the adjacent bonds poor protease substrates. Valine terminates the peptide with a branched hydrophobic side chain and a free carboxyl.

Research material referenced

KPV 10mg — third-party HPLC tested

View — £24.99

Why proline matters even here

In a three-residue peptide, one proline is a third of the molecule. Its ring removes the backbone amide hydrogen and locks rotation, which both constrains the shape and gives real protease resistance. For such a short peptide that constraint is proportionally more significant than the same residue would be in a longer chain.

The analytical problem

No tryptophan, tyrosine or phenylalanine means no usable absorbance at 280 nm, so spectrophotometric quantification is unavailable. At 342 Da the molecule is also near the lower end of what reverse-phase HPLC separates well, since very small polar molecules retain poorly on hydrophobic columns. KPV is genuinely awkward to characterise.

What is chemically absent

No cysteine, so no disulfide chemistry. No methionine, so no oxidation satellite at +16 Da. No asparagine, so no deamidation hotspot. As with Selank and TB-500, the common degradation routes simply do not apply, leaving hydrolysis and physical loss to surfaces.

Extended research context

The KPV deep dive

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Research applications

▸Melanocortin fragment structure-activity research
▸NF-kappaB pathway and cytokine production studies in culture
▸Murine models of induced intestinal inflammation
▸Targeted peptide delivery and carrier system development
▸Comparative work on parent hormones and isolated fragments
▸Analytical method development for very short peptides

Handling checklist

✓Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
✓Do not search PubChem for 'KPV' - it returns an unrelated organic acid
✓Store lyophilised, cold, dry and dark
✓Use low-binding consumables; a small cationic peptide adsorbs to surfaces
✓Reconstitute gently down the vial wall and swirl, never shake
✓Aliquot into single-use volumes to avoid freeze-thaw cycling
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'KPV' to verify a certificate

Fix: That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Treating KPV and alpha-MSH findings as interchangeable

Fix: They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

✗ Assuming a colitis model result speaks to inflammatory bowel disease

Fix: Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

✗ Expecting to quantify KPV by absorbance at 280 nm

Fix: There is no aromatic residue in the sequence, so there is no usable absorbance there.

✗ Attributing unexplained low recovery to degradation

Fix: KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Can KPV fold?: No. Three residues have two peptide bonds and no capacity for secondary structure. Any activity comes from side-chain chemistry and proline's local geometry.
Can it be quantified at 280 nm?: No. There is no aromatic residue, so there is no usable absorbance there.
Why does one proline matter so much?: In a tripeptide it is a third of the molecule. It locks local geometry and makes adjacent bonds poor protease substrates.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum